Literature DB >> 28220290

Epidemiology of amyotrophic lateral sclerosis in Southern Germany.

Angela Rosenbohm1, Raphael S Peter2, Siegfried Erhardt2, Dorothée Lulé1, Dietrich Rothenbacher2, Albert C Ludolph3, Gabriele Nagel2.   

Abstract

The objective of this study is to determine the current distribution of clinical phenotypes and to estimate future trends of ALS incidence in Western societies. We report on a clinical-epidemiological registry with a capture-recapture rate of >80% and population-based case-control study in ALS patients in South Western Germany. 1163 incidents of ALS were registered. Clinical and neuropsychological data were prospectively collected from 699 cases. The mean age at onset was 66.6 (SD = 11.6) years in prospective cases (N = 699). The site of onset was more frequently bulbar (34.1%) than lumbosacral (30.7%), cervical (27.0%), or thoracic (3.1%). Cognitive deficits (ranging from 27.5 to 42.1%, depending on the screening instrument) and behavioral changes (29%) were frequently detected. The incidence rate dropped markedly after 79 years of age, and bulbar onset as well as cognitive impairment were more frequent in ALS cases >75 years. The mean survival time of ALS cases from first paresis was 31 months. The age-standardized incidence rate (ASR) of ALS in 2012/2013 was found to be 2.4 (95% CI 2.2-2.7) per 100,000 person-years (resulting in an ASR of 3.1/100,000 with 100% coverage). Based on the predicted age distribution of the German population, the incidence of ALS was estimated to be 4.5/100,000 for men and 3.3/100,000 for women in the year 2050. ALS prevalence will rise to about 9.2-9.8/100,000 person-years in Germany in 2050. An increased proportion of patients with bulbar onset and/or cognitive deficits can be used as basic epidemiologic data on ALS for future health care decisions.

Entities:  

Keywords:  Aging; Amyotrophic lateral sclerosis; Cognitive impairment; Registry

Mesh:

Year:  2017        PMID: 28220290     DOI: 10.1007/s00415-017-8413-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: a cross-sectional comparison of established screening tools in a German-Swiss population.

Authors:  Dorothée Lulé; Christian Burkhardt; Susanne Abdulla; Sarah Böhm; Katja Kollewe; Ingo Uttner; Sharon Abrahams; Thomas H Bak; Susanne Petri; Markus Weber; Albert C Ludolph
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-08       Impact factor: 4.092

3.  Survival of patients with amyotrophic lateral sclerosis in a population-based registry.

Authors:  A Millul; E Beghi; G Logroscino; A Micheli; E Vitelli; A Zardi
Journal:  Neuroepidemiology       Date:  2005-06-13       Impact factor: 3.282

4.  El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.

Authors:  B R Brooks
Journal:  J Neurol Sci       Date:  1994-07       Impact factor: 3.181

5.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

Review 6.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 7.  Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues.

Authors:  G Logroscino; B J Traynor; O Hardiman; A Chio'; P Couratier; J D Mitchell; R J Swingler; E Beghi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-01       Impact factor: 10.154

8.  Cognitive changes predict functional decline in ALS: a population-based longitudinal study.

Authors:  Marwa Elamin; Peter Bede; Susan Byrne; Norah Jordan; Laura Gallagher; Brona Wynne; Caoimhe O'Brien; Julie Phukan; Catherine Lynch; Niall Pender; Orla Hardiman
Journal:  Neurology       Date:  2013-04-03       Impact factor: 9.910

9.  Amyotrophic lateral sclerosis in Sweden, 1991-2005.

Authors:  Fang Fang; Unnur Valdimarsdóttir; Rino Bellocco; Lars-Olof Ronnevi; Pär Sparén; Katja Fall; Weimin Ye
Journal:  Arch Neurol       Date:  2009-04

10.  Cancer and aging: Epidemiology and methodological challenges.

Authors:  Jacob K Pedersen; Gerda Engholm; Axel Skytthe; Kaare Christensen
Journal:  Acta Oncol       Date:  2016-01-12       Impact factor: 4.089

View more
  18 in total

1.  Changing epidemiology of motor neurone disease in Scotland.

Authors:  Danielle J Leighton; Judith Newton; Laura J Stephenson; Shuna Colville; Richard Davenport; George Gorrie; Ian Morrison; Robert Swingler; Siddharthan Chandran; Suvankar Pal
Journal:  J Neurol       Date:  2019-02-25       Impact factor: 4.849

2.  Increased pyroptosis activation in white matter microglia is associated with neuronal loss in ALS motor cortex.

Authors:  Evelien Van Schoor; Simona Ospitalieri; Sebastiaan Moonen; Sandra O Tomé; Alicja Ronisz; Orkun Ok; Jochen Weishaupt; Albert C Ludolph; Philip Van Damme; Ludo Van Den Bosch; Dietmar Rudolf Thal
Journal:  Acta Neuropathol       Date:  2022-07-22       Impact factor: 15.887

3.  Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017.

Authors:  Paul Mehta; Jaime Raymond; Reshma Punjani; Moon Han; Theodore Larson; Wendy Kaye; Lorene M Nelson; Barbara Topol; Oleg Muravov; Corina Genson; D Kevin Horton
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2022-04-15       Impact factor: 3.528

4.  Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS.

Authors:  Anika M Helferich; Sarah J Brockmann; Jörg Reinders; Dhruva Deshpande; Karlheinz Holzmann; David Brenner; Peter M Andersen; Susanne Petri; Dietmar R Thal; Jens Michaelis; Markus Otto; Steffen Just; Albert C Ludolph; Karin M Danzer; Axel Freischmidt; Jochen H Weishaupt
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

5.  Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany.

Authors:  Angela Rosenbohm; Mingsheng Liu; Gabriele Nagel; Raphael S Peter; Bo Cui; Xiaoguang Li; Jan Kassubek; Dietrich Rothenbacher; Dorothée Lulé; Liying Cui; Albert C Ludolph
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

6.  Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis.

Authors:  Angela Rosenbohm; Gabriele Nagel; Raphael S Peter; Torben Brehme; Wolfgang Koenig; Luc Dupuis; Dietrich Rothenbacher; Albert C Ludolph
Journal:  JAMA Neurol       Date:  2018-05-01       Impact factor: 18.302

7.  Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia.

Authors:  Raphael Simon Peter; Angela Rosenbohm; Luc Dupuis; Torben Brehme; Jan Kassubek; Dietrich Rothenbacher; Gabriele Nagel; Albert Christian Ludolph
Journal:  Eur J Epidemiol       Date:  2017-10-03       Impact factor: 8.082

8.  Prognostic factors in ALS: a comparison between Germany and China.

Authors:  Johannes Dorst; Lu Chen; Angela Rosenbohm; Dong-Sheng Fan; Albert C Ludolph; Jens Dreyhaupt; Annemarie Hübers; Joachim Schuster; Jochen H Weishaupt; Jan Kassubek; Burkhard Gess; Thomas Meyer; Ute Weyen; Andreas Hermann; Jürgen Winkler; Torsten Grehl; Tim Hagenacker; Paul Lingor; Jan C Koch; Anne Sperfeld; Susanne Petri; Julian Großkreutz; Moritz Metelmann; Joachim Wolf; Andrea S Winkler; Thomas Klopstock; Matthias Boentert; Siw Johannesen; Alexander Storch; Bertold Schrank; Daniel Zeller; Xiao-Lu Liu; Lu Tang
Journal:  J Neurol       Date:  2019-03-28       Impact factor: 4.849

Review 9.  Antisense oligonucleotides in neurological disorders.

Authors:  Claudia D Wurster; Albert C Ludolph
Journal:  Ther Adv Neurol Disord       Date:  2018-05-23       Impact factor: 6.570

10.  Edaravone: a baby in the bathwater?

Authors:  Albert Ludolph
Journal:  Ther Adv Neurol Disord       Date:  2017-07-24       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.